S
Synchron
Biotech & Life Sciences · New York City, United States · Founded 2012
Developing implantable brain-computer interfaces to restore neurological function and enable direct communication between the brain and external devices MoreLess
Synchron is a pioneering company in the medical technology sector, aiming to revolutionize healthcare by providing unprecedented access to brain data. Founded in 2012, Synchron focuses on developing brain-computer interface (BCI) technology that allows individuals to control digital devices using their thoughts. This technology is particularly transformative for patients with severe paralysis, offering them a new level of autonomy and social connection.
The company's flagship product involves a minimally invasive endovascular procedure, akin to the placement of stents, which eliminates the need for open brain surgery. This procedure allows the BCI to be implanted safely and efficiently, making it accessible to a broader range of patients.
Synchron primarily serves patients with neurological conditions that impair their ability to communicate or move. These clients benefit from the ability to control computers and other digital devices using their thoughts, significantly improving their quality of life. The company operates in the medical technology market, which is rapidly growing due to advancements in healthcare and increasing demand for innovative treatments.
The business model of Synchron revolves around the development, clinical testing, and commercialization of its BCI technology. The company generates revenue through the sale of its medical devices and related services. Additionally, Synchron may engage in partnerships with healthcare providers and institutions to expand the reach and application of its technology.
The leadership team at Synchron comprises global experts in neuroscience, vascular bionics, and medical technology, including CEO Tom Oxley and Founding Director Nick Opie. Their combined expertise drives the company's mission to empower patients and transform medicine.
In summary, Synchron is at the forefront of medical innovation, offering groundbreaking solutions for patients with severe neurological impairments. By leveraging advanced BCI technology, the company is making significant strides in improving patient autonomy and social connectivity.
Keywords: Brain-computer interface, minimally invasive, endovascular procedure, neurological conditions, patient autonomy, digital control, medical technology, healthcare innovation, paralysis treatment, brain data.
Company overview
Synchron company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- New York City, United States
- Employees
- 131
- Open positions
- 37
- Dealroom signal
- 72.8
- Investment activity
- 1 companies · latest Feb 2024
- Capital deployed
- —
- Preferred round
- GROWTH EQUITY NON VC
Valuation & funding
Synchron funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Nov 2025 | $200M | $900M | Qatar Investment Authority · Bezos Expeditions · ARCH Venture Partners · Protocol Labs | ↗ |
| SERIES COther financing | Dec 2022 | $75M | $300M | ARCH Venture Partners · Forepont Capital Partners · Alumni Ventures · Reliance Industries | ↗ |
| LATE VCOther financing | Feb 2022 | $0 | — | Max Hodak | ↗ |
| GRANTOther financing | Aug 2021 | $10M | — | National Institutes of Health | — |
| SERIES BOther financing | Jun 2021 | $34M | $135M | Forepont Capital Partners · Subversive Capital · ID8 Investments · Thomas Reardon | ↗ |
| GRANTOther financing | Jul 2020 | Undisclosed | — | ||
| SERIES AOther financing | Apr 2017 | DARPA · NeuroTechnology Investors | ↗ | ||
| SPINOUTOther financing | Jan 2012 | University of Melbourne | ↗ | ||
| EARLY VCOther financing | Jan 2005 | Sigma Partners | — |
Growth signals
Synchron website traffic
Latest recorded traffic for Synchron is 29K monthly website visits, up 0% over the last three months. Synchron's team declined 0.8% over the past year.
Hiring
Open positions at Synchron
Current openings linked to this company in Dealroom.
Comparisons
Synchron compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Synchron investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Synchron's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Synchron has talent and traffic
team presence
In the news
Latest news about Synchron
Recent press, funding announcements, and product moves mentioning Synchron — open to read from the original sources.
Market sentiment
What the market is saying about Synchron
An AI-synthesized read of the highest-engagement posts about Synchron on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Synchron’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.



































